Zeltia Group

Zeltia: Report at 31 December 2004

    Madrid, Spain (ots/PRNewswire) -


    - Yondelis:

    - Due to the good results presented at the ASCO (American Society of Clinical Oncology) meeting, the randomised pivotal trial on soft-tissue sarcoma was expanded so as to compile a dossier for a regulatory application.

    - Results presented on ovarian cancer formed the basis for preparing Phase III trials in combination with Doxil.

    - The FDA (Food and Drug Administration) granted orphan drug designation to Yondelis for the treatment of soft-tissue sarcoma.

    - Aplidin:

    - The Phase II trial on haematological tumours commenced.

    - The FDA granted orphan drug designation to Aplidin for the treatment of multiple myeloma and acute lymphoblastic leukaemia

    - The EMEA (European Medicines Agency) granted orphan drug status for the treatment of multiple myeloma.

    - Aplidin obtained IND (Investigational New Drug) designation to commence clinical trials in the US.   - Zalypsis: Pre-clinical trials concluded to start clinical trials


    - The private placement of 25% of NeuroPharma was completed, raising 15 million euro.


    - Group net revenues increased by 7% year-on-year to 79 million euro.

    - The net cash position (cash + cash equivalents - short-term bank debt) amounted to 86 million euro.

ots Originaltext: Zeltia Group
Im Internet recherchierbar: http://www.newsaktuell.ch

Isabel Lozano, CEO, PHARMAMAR,S.A., C/ Reyes, 1.Colmenar Viejo,
Madrid, Telephone +34-91-846-60-00. Catherine Moukheibir, Head of
Capital Market Strategy, ZELTIA, S.A., José Abascal, 2, Madrid,
Telephone +34-91-444-45-00. M(a) Luisa de Francia, CFO, ZELTIA, S.A.,
José Abascal, 2, Madrid, Telephone +34-91-444-45-00

Weitere Meldungen: Zeltia Group

Das könnte Sie auch interessieren: